Oestriol

For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause: the lowest dose that will control symptoms should be selected. Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage is 1 - 2 mg daily. Administration should be cyclic [e.g. 4 weeks on and 1 week off]. For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure: Treatment is initiated with a dose of 1 - 2 mg daily. For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease: 10 mg TID for at least three months. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only: 1-2 mg TID. The effectiveness of therapy can be judged by phosphatase as well as by symptomatic improvement of the patient determinations. For the prevention of osteoporosis: To be initiated as soon as possible after menopause. 0.5 mg daily administered cyclically [i.e., 23 days on and 5 days off]. The dosage may be adjusted if necessary to control concurrent menopausal symptoms. Discontinuation of estrogen replacement therapy may re-establish the natural rate of bone loss.

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.